The Oncology Brothers and Patrick Forde, MBBCh, outline immunotherapy options for patients with non–small cell lung cancer and the role of PD-L1 in informing treatment decisions.
Zongertinib Yields Meaningful Responses in Pretreated HER2-Mutated NSCLC
Phase 1b data also show encouraging preliminary intracranial activity with zongertinib among patients with HER2-mutant non–small cell lung cancer.
Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology
Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.
Amivantamab Combo Shows Improved OS Trend Vs Osimertinib in EGFR+ NSCLC
Amivantamab/lazertinib also reduces the risk of second progression or death compared with osimertinib in the phase 3 MARIPOSA trial.
Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery
Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.
Encorafenib Combo Earns European Approval in Advanced BRAF+ NSCLC
Data from the phase 2 PHAROS trial support the European Commission’s approval of encorafenib/binimetinib in NSCLC harboring a BRAF V600E mutation.
Adjuvant Chemotherapy May Have Survival Benefit in Stage III Locally Advanced NSCLC
Favorable recurrence-free survival and overall survival outcomes were not observed in the overall patient cohort receiving adjuvant chemotherapy for advanced NSCLC.